{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:45:23Z","timestamp":1794271523265,"version":"4.9.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1146996"],"award-info":[{"award-number":["OPP1146996"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI149670, AI145801, AI129797, AI128751, AI126603, AI124377, OD024917"],"award-info":[{"award-number":["AI149670, AI145801, AI129797, AI128751, AI126603, AI124377, OD024917"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI106408"],"award-info":[{"award-number":["AI106408"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    HIV-1 therapy with single or dual broadly neutralizing antibodies (bNAbs) has shown viral escape, indicating that at least a triple bNAb therapy may be needed for robust suppression of viremia. We performed a two-part study consisting of a single-center, randomized, double-blind, dose-escalation, placebo-controlled first-in-human trial of the HIV-1 V2-glycan-specific antibody PGDM1400 alone or in combination with the V3-glycan-specific antibody PGT121 in 24 adults without HIV in part 1, as well as a multi-center, open-label trial of the combination of PGDM1400, PGT121 and the CD4-binding-site antibody VRC07-523LS in five viremic adults living with HIV not on antiretroviral therapy (ART) in part 2 (\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03205917\">NCT03205917<\/jats:ext-link>\n                    ). The primary endpoints were safety, tolerability and pharmacokinetics for both parts and antiviral activity among viremic adults living with HIV and not on ART for part 2 of the study. The secondary endpoints were changes in CD4\n                    <jats:sup>+<\/jats:sup>\n                    T cell counts and development of HIV-1 sequence variations associated with PGDM1400, PGT121 and VRC07-523LS resistance in part 2. Intravenously administered PGDM1400 was safe and well-tolerated at doses up to 30\u2009mg\u2009kg\n                    <jats:sup>\u22121<\/jats:sup>\n                    and when given in combination with PGT121 and VRC07-523LS. A single intravenous infusion of 20\u2009mg\u2009kg\n                    <jats:sup>\u22121<\/jats:sup>\n                    of each of the three antibodies reduced plasma HIV RNA levels in viremic individuals by a maximum mean of 2.04 log\n                    <jats:sub>10<\/jats:sub>\n                    copies per ml; however, viral rebound occurred in all participants within a median of 20\u2009days after nadir. Rebound viruses demonstrated partial to complete resistance to PGDM1400 and PGT121 in vitro, whereas susceptibility to VRC07-523LS was preserved. Viral rebound occurred despite mean VRC07-523LS serum concentrations of 93\u2009\u00b5g\u2009ml\n                    <jats:sup>\u22121<\/jats:sup>\n                    . The trial met the pre-specified endpoints. Our data suggest that future bNAb combinations likely need to achieve broad antiviral activity, while also maintaining high serum concentrations, to mediate viral control.\n                  <\/jats:p>","DOI":"10.1038\/s41591-022-01815-1","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T12:10:09Z","timestamp":1652357409000},"page":"1288-1296","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":142,"title":["Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial"],"prefix":"10.1038","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4687-9626","authenticated-orcid":false,"given":"Boris","family":"Julg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn E.","family":"Stephenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kshitij","family":"Wagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina C.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Zash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0817-9370","authenticated-orcid":false,"given":"Stephen","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Ansel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Kanjilal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Nkolola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria E. K.","family":"Walker-Sperling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0040-1328","authenticated-orcid":false,"given":"Jasper","family":"Ophel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Yanosick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica N.","family":"Borducchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7595-6205","authenticated-orcid":false,"given":"Lori","family":"Maxfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1978-088X","authenticated-orcid":false,"given":"Peter","family":"Abbink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2105-7503","authenticated-orcid":false,"given":"Lauren","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole L.","family":"Yates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8664-9307","authenticated-orcid":false,"given":"Martina S.","family":"Wesley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Hassell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4786-1003","authenticated-orcid":false,"given":"Huub C.","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"deCamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2258-5276","authenticated-orcid":false,"given":"Bryan T.","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica W.","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena E.","family":"Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Gama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Koup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Mascola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Monczor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Lupo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte-Paige","family":"Rolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Arduino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"DeJesus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia D.","family":"Tomaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Seaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2026-5757","authenticated-orcid":false,"given":"Bette","family":"Korber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5127-4659","authenticated-orcid":false,"given":"Dan H.","family":"Barouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,12]]},"reference":[{"key":"1815_CR1","doi-asserted-by":"publisher","first-page":"319ra206","DOI":"10.1126\/scitranslmed.aad5752","volume":"7","author":"RM Lynch","year":"2015","unstructured":"Lynch, R. M. et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci. Transl. Med. 7, 319ra206 (2015).","journal-title":"Sci. Transl. Med."},{"key":"1815_CR2","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nm.4268","volume":"23","author":"M Caskey","year":"2017","unstructured":"Caskey, M. et al. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat. Med. 23, 185\u2013191 (2017).","journal-title":"Nat. Med."},{"key":"1815_CR3","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nature14411","volume":"522","author":"M Caskey","year":"2015","unstructured":"Caskey, M. et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522, 487\u2013491 (2015).","journal-title":"Nature"},{"key":"1815_CR4","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/s41591-018-0186-4","volume":"24","author":"Y Bar-On","year":"2018","unstructured":"Bar-On, Y. et al. Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nat. Med. 24, 1701\u20131707 (2018).","journal-title":"Nat. Med."},{"key":"1815_CR5","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1016\/S2352-3018(19)30053-0","volume":"6","author":"TA Crowell","year":"2019","unstructured":"Crowell, T. A. et al. Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet HIV 6, e297\u2013e306 (2019).","journal-title":"Lancet HIV"},{"key":"1815_CR6","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","volume":"375","author":"KJ Bar","year":"2016","unstructured":"Bar, K. J. et al. Effect of HIV antibody VRC01 on viral rebound after treatment interruption. N. Engl. J. Med. 375, 2037\u20132050 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1815_CR7","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nature18929","volume":"535","author":"JF Scheid","year":"2016","unstructured":"Scheid, J. F. et al. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature 535, 556\u2013560 (2016).","journal-title":"Nature"},{"key":"1815_CR8","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","volume":"561","author":"P Mendoza","year":"2018","unstructured":"Mendoza, P. et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature 561, 479\u2013484 (2018).","journal-title":"Nature"},{"key":"1815_CR9","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1146\/annurev-immunol-080219-023629","volume":"38","author":"KE Stephenson","year":"2020","unstructured":"Stephenson, K. E., Wagh, K., Korber, B. & Barouch, D. H. Vaccines and broadly neutralizing antibodies for HIV-1 prevention. Annu. Rev. Immunol. 38, 673\u2013703 (2020).","journal-title":"Annu. Rev. Immunol."},{"key":"1815_CR10","doi-asserted-by":"publisher","first-page":"17624","DOI":"10.1073\/pnas.1415789111","volume":"111","author":"D Sok","year":"2014","unstructured":"Sok, D. et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc. Natl Acad. Sci. USA 111, 17624\u201317629 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1815_CR11","doi-asserted-by":"publisher","first-page":"eaal1321","DOI":"10.1126\/scitranslmed.aal1321","volume":"9","author":"B Julg","year":"2017","unstructured":"Julg, B. et al. Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Sci. Transl. Med. 9, eaal1321 (2017).","journal-title":"Sci. Transl. Med."},{"key":"1815_CR12","doi-asserted-by":"publisher","first-page":"eaao4235","DOI":"10.1126\/scitranslmed.aao4235","volume":"9","author":"B Julg","year":"2017","unstructured":"Julg, B. et al. Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail. Sci. Transl. Med. 9, eaao4235 (2017).","journal-title":"Sci. Transl. Med."},{"key":"1815_CR13","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nature13612","volume":"514","author":"SY Ko","year":"2014","unstructured":"Ko, S. Y. et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 514, 642\u2013645 (2014).","journal-title":"Nature"},{"key":"1815_CR14","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.immuni.2017.03.017","volume":"46","author":"JH Lee","year":"2017","unstructured":"Lee, J. H. et al. A broadly neutralizing antibody targets the dynamic HIV envelope trimer apex via a long, rigidified, and anionic \u03b2-hairpin structure. Immunity 46, 690\u2013702 (2017).","journal-title":"Immunity"},{"key":"1815_CR15","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.chom.2019.07.016","volume":"26","author":"CA Bricault","year":"2019","unstructured":"Bricault, C. A. et al. HIV-1 neutralizing antibody signatures and application to epitope-targeted vaccine design. Cell Host Microbe 26, 296 (2019).","journal-title":"Cell Host Microbe"},{"key":"1815_CR16","doi-asserted-by":"publisher","first-page":"W213","DOI":"10.1093\/nar\/gkv404","volume":"43","author":"H Yoon","year":"2015","unstructured":"Yoon, H. et al. CATNAP: a tool to compile, analyze and tally neutralizing antibody panels. Nucleic Acids Res. 43, W213\u2013W219 (2015).","journal-title":"Nucleic Acids Res."},{"key":"1815_CR17","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.immuni.2018.04.029","volume":"48","author":"PD Kwong","year":"2018","unstructured":"Kwong, P. D. & Mascola, J. R. HIV-1 vaccines based on antibody identification, B cell ontogeny, and epitope structure. Immunity 48, 855\u2013871 (2018).","journal-title":"Immunity"},{"key":"1815_CR18","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1038\/s41591-021-01509-0","volume":"27","author":"KE Stephenson","year":"2021","unstructured":"Stephenson, K. E. et al. Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. Nat. Med. 27, 1718\u20131724 (2021).","journal-title":"Nat. Med."},{"key":"1815_CR19","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.immuni.2016.08.016","volume":"45","author":"JM Steichen","year":"2016","unstructured":"Steichen, J. M. et al. HIV vaccine design to target germline precursors of glycan-dependent broadly neutralizing antibodies. Immunity 45, 483\u2013496 (2016).","journal-title":"Immunity"},{"key":"1815_CR20","doi-asserted-by":"publisher","first-page":"eaay7199","DOI":"10.1126\/science.aay7199","volume":"366","author":"KO Saunders","year":"2019","unstructured":"Saunders, K. O. et al. Targeted selection of HIV-specific antibody mutations by engineering B cell maturation. Science 366, eaay7199 (2019).","journal-title":"Science"},{"key":"1815_CR21","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1128\/JVI.01791-15","volume":"90","author":"NA Doria-Rose","year":"2016","unstructured":"Doria-Rose, N. A. et al. New member of the V1V2-directed CAP256-VRC26 lineage that shows increased breadth and exceptional potency. J. Virol. 90, 76\u201391 (2016).","journal-title":"J. Virol."},{"key":"1815_CR22","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1093\/infdis\/jit272","volume":"208","author":"A Andrade","year":"2013","unstructured":"Andrade, A. et al. Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248. J. Infect. Dis. 208, 884\u2013891 (2013).","journal-title":"J. Infect. Dis."},{"key":"1815_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/srep32947","volume":"6","author":"M Hoenigl","year":"2016","unstructured":"Hoenigl, M. et al. Rapid HIV viral load suppression in those initiating antiretroviral therapy at first visit after HIV diagnosis. Sci. Rep. 6, 32947 (2016).","journal-title":"Sci. Rep."},{"key":"1815_CR24","doi-asserted-by":"publisher","first-page":"e1006860","DOI":"10.1371\/journal.ppat.1006860","volume":"14","author":"K Wagh","year":"2018","unstructured":"Wagh, K. et al. Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections. PLoS Pathog. 14, e1006860 (2018).","journal-title":"PLoS Pathog."},{"key":"1815_CR25","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1126\/science.aan8630","volume":"358","author":"L Xu","year":"2017","unstructured":"Xu, L. et al. Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. Science 358, 85\u201390 (2017).","journal-title":"Science"},{"key":"1815_CR26","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/nature12744","volume":"503","author":"DH Barouch","year":"2013","unstructured":"Barouch, D. H. et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503, 224\u2013228 (2013).","journal-title":"Nature"},{"key":"1815_CR27","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1126\/science.aaf1279","volume":"352","author":"CL Lu","year":"2016","unstructured":"Lu, C. L. et al. Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science 352, 1001\u20131004 (2016).","journal-title":"Science"},{"key":"1815_CR28","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1126\/science.aaf0972","volume":"352","author":"T Schoofs","year":"2016","unstructured":"Schoofs, T. et al. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science 352, 997\u20131001 (2016).","journal-title":"Science"},{"key":"1815_CR29","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nature21435","volume":"543","author":"Y Nishimura","year":"2017","unstructured":"Nishimura, Y. et al. Early antibody therapy can induce long-lasting immunity to SHIV. Nature 543, 559\u2013563 (2017).","journal-title":"Nature"},{"key":"1815_CR30","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41586-018-0600-6","volume":"563","author":"EN Borducchi","year":"2018","unstructured":"Borducchi, E. N. et al. Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. Nature 563, 360\u2013364 (2018).","journal-title":"Nature"},{"key":"1815_CR31","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","volume":"384","author":"L Corey","year":"2021","unstructured":"Corey, L. et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N. Engl. J. Med. 384, 1003\u20131014 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1815_CR32","doi-asserted-by":"publisher","first-page":"12449","DOI":"10.1128\/JVI.01708-08","volume":"82","author":"GD Tomaras","year":"2008","unstructured":"Tomaras, G. D. et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J. Virol. 82, 12449\u201312463 (2008).","journal-title":"J. Virol."},{"key":"1815_CR33","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","volume":"366","author":"BF Haynes","year":"2012","unstructured":"Haynes, B. F. et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366, 1275\u20131286 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1815_CR34","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/mi.2012.107","volume":"6","author":"NL Yates","year":"2013","unstructured":"Yates, N. L. et al. HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life. Mucosal Immunol. 6, 692\u2013703 (2013).","journal-title":"Mucosal Immunol."},{"key":"1815_CR35","doi-asserted-by":"publisher","first-page":"709994","DOI":"10.3389\/fimmu.2021.709994","volume":"12","author":"MS Wesley","year":"2021","unstructured":"Wesley, M. S. et al. Validation of a triplex pharmacokinetic assay for simultaneous quantitation of HIV-1 broadly neutralizing antibodies PGT121, PGDM1400, and VRC07-523-LS. Front Immunol. 12, 709994 (2021).","journal-title":"Front Immunol."},{"key":"1815_CR36","first-page":"Unit 12.11","volume":"Chapter 12","author":"DC Montefiori","year":"2005","unstructured":"Montefiori, D. C. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr. Protoc. Immunol. Chapter 12, Unit 12.11 (2005).","journal-title":"Curr. Protoc. Immunol."},{"key":"1815_CR37","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1128\/JVI.02108-09","volume":"84","author":"MS Seaman","year":"2010","unstructured":"Seaman, M. S. et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 84, 1439\u20131452 (2010).","journal-title":"J. Virol."},{"key":"1815_CR38","doi-asserted-by":"publisher","first-page":"10108","DOI":"10.1128\/JVI.79.16.10108-10125.2005","volume":"79","author":"M Li","year":"2005","unstructured":"Li, M. et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79, 10108\u201310125 (2005).","journal-title":"J. Virol."},{"key":"1815_CR39","doi-asserted-by":"publisher","first-page":"11776","DOI":"10.1128\/JVI.01730-06","volume":"80","author":"M Li","year":"2006","unstructured":"Li, M. et al. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J. Virol. 80, 11776\u201311790 (2006).","journal-title":"J. Virol."},{"key":"1815_CR40","doi-asserted-by":"publisher","first-page":"7552","DOI":"10.1073\/pnas.0802203105","volume":"105","author":"BF Keele","year":"2008","unstructured":"Keele, B. F. et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl Acad. Sci. USA 105, 7552\u20137557 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1815_CR41","unstructured":"Sidak, Z., Sen, P. K. & Hajek, J. Theory of Rank Tests (Academic Press, 1999)."},{"key":"1815_CR42","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2307\/2532051","volume":"45","author":"LI Lin","year":"1989","unstructured":"Lin, L. I. A concordance correlation coefficient to evaluate reproducibility. Biometrics 45, 255\u2013268 (1989).","journal-title":"Biometrics"},{"key":"1815_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04217-5","volume":"9","author":"H Song","year":"2018","unstructured":"Song, H. et al. Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection. Nat. Commun. 9, 1928 (2018).","journal-title":"Nat. Commun."},{"key":"1815_CR44","doi-asserted-by":"publisher","first-page":"e1005520","DOI":"10.1371\/journal.ppat.1005520","volume":"12","author":"K Wagh","year":"2016","unstructured":"Wagh, K. et al. Optimal combinations of broadly neutralizing antibodies for prevention and treatment of HIV-1 clade C infection. PLoS Pathog. 12, e1005520 (2016).","journal-title":"PLoS Pathog."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01815-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01815-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01815-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T11:05:37Z","timestamp":1655463937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01815-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,12]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1815"],"URL":"https:\/\/doi.org\/10.1038\/s41591-022-01815-1","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,12]]},"assertion":[{"value":"17 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.C.G. is an employee of Icosavax Inc. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}